5 Oversold Global Stocks To Buy
Mesoblast Limited (NASDAQ:MESO) is an Australian biotechnology company that is headquartered in Melbourne.
Galmed Pharmaceuticals Ltd. (GLMD)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 80,177 | $39,287 | +155% | 0% |
| 2. | Citadel Investment Group Ken Griffin | 11,382 | $5,500 | -71% | 0% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 22,396 | $10,822 | 0% | |
| 2. | 16,445 | $8,058 | 0% | |
| 3. | 11,971 | $5,866 | 0% | |
| 4. | 2,546 | $1,248 | 0% | |
| 5. | 600 | $294 | 0% |
News See All
These 10 Penny Stocks are Trending on Reddit
In this article, we take a look at the 10 penny stocks that are trending on Reddit.
Is Galmed Pharmaceuticals Ltd (GLMD) A Good Stock To Buy?
In this article we will check out the progression of hedge fund sentiment towards Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) and determine whether it is a good investment right now.
Here is What Hedge Funds Think About Galmed Pharmaceuticals Ltd (GLMD)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Do Hedge Funds Love Galmed Pharmaceuticals Ltd (GLMD)?
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good.
Nantahala Capital Management’s Returns, AUM, and Holdings
Nantahala Capital Management is a New Haven-based hedge fund founded in 2004 by 26-year-old Wilmot Harkey.
Market Movers Today: Tetraphase Pharmaceuticals Inc (TTPH), Twilio Inc (TWLO), Genesco Inc. (GCO), Nektar Therapeutics (NKTR), and More
Tetraphase Pharmaceuticals Inc's Ignite3 trial evaluating the company's lead drug candidate eravacycline for treating complicated urinary tract infections, or cUTIs, failed to ace a late-stage trial.
13G Filing: 683 Capital Partners and Galmed Pharmaceuticals Ltd (GLMD)
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing ...
Why Collegium Pharmaceuticals Inc (COLL), Galmed Pharmaceuticals Ltd (GLMD) and Three Other Stocks Are Registering Significant Gains Today
As the main indices are heading towards ending today's session in the green territory, let's take a look at five stocks that are registering significant gains today.
Hedge Fund Resource Center